Mangoceuticals (MNGO), which plans to marketplace an erectile dysfunction procedure known as MangoED by way of its proprietary web-site, has submitted for a $5M initial public featuring.
The men’s health and fitness products developer explained in a filing that it designs to supply 1.25M shares priced involving $3 and $5, which would elevated all over $5M if priced at the midpoint. The organization has also registered another 4.69M shares for resale under a independent prospectus.
Mangoceuticals hopes to listing its shares on Nasdaq underneath the symbol MNGO. Boustead Securities is serving as direct bookrunner.
The Dallas, Texas-based corporation has created a speedy-dissolving tablet for erectile dysfunction that includes very same lively ingredient uncovered in Cialis, also identified as tadalafil. Mangoceuticals plans to market place solution instantly by way of its internet site www.mangoRx.com.
The organization also options to give telehealth services for men’s health issues with medical professionals by its system. Solutions will be provided by Brighter MD, which does business as Doctegrity.
Mangoceuticals’ products will be compounded, packaged and shipped by Epiq Scripts, a vast majority owned subsidiary of Mangoceuticals’ former owner, American Intercontinental. Mangoceuticals’ main executive, Jacob Cohen, also serves as CEO of American Intercontinental.
The business mentioned it options to commence offering “industrial portions” of MangoED in Q1 2023 pursuing the offering.
For additional on Mangoceuticals, check out Donovan Jones’s “Mangoceuticals Aims for $5M Micro-IPO.”